Skip to content
Companies

Arpeggio Biosciences

Transcriptomics and machine learning for drug discovery

Raised to date

$24.1M

of $39.9M offered across 2 Form D filings

Still open
$15.8M
Investors
14
Last filed
Nov 24, 2025

About

Arpeggio Biosciences, Inc. is a biotech innovator specializing in advanced drug discovery solutions through the integration of transcriptomics and artificial intelligence. By leveraging cutting-edge technology and vast datasets, the company is poised to revolutionize the identification of effective treatments for complex diseases.

Arpeggio's GRETA™ platform offers a unique combination of machine learning and comprehensive biological assays that facilitate a deeper understanding of complex cellular networks, setting the company apart in the pharmaceutical landscape.

Funding

Mar 20252026
Now

$35.3M round, first sold Nov 2025: $20M sold, $15.3M still open

  • EquityFiled Nov 24, 2025Form D
    $20M/ $35.3M
  • EquityFiled Mar 27, 2025Form D
    $4M/ $4.6M

Product

GRETA™ Platform

Drug Discovery Technology

The GRETA™ platform represents a cutting-edge technological frontier in drug discovery, merging proprietary biological assays with advanced machine learning algorithms. This synergy enables rapid, high-resolution analyses of cellular changes in response to drug treatments, pushing the boundaries of conventional drug development practices.

  • Comprehensive analysis of cellular dynamics
  • Proprietary chemotranscriptomics database
  • Predictive capabilities for drug toxicity

Built for

Pharmaceutical companies and clinical researchers

People on file